Human Lyb‐2 homolog CD72 is a marker for progenitor B‐cell leukemias

Publisher Website
Google Scholar
Abstract
S‐HCL 2 is the prototype antibody of the recently defined CD72 cluster (human Lyb‐2). Under nonreducing conditions, S‐HCL 2 monoclonal antibody (mAb) precipitates a glycoprotein of 80–86 kDa. Under reducing conditions, a dimer of 43 and 39 kDa, with core proteins of 40 and 36 kDa, is precipitated. CD72 expression in normal and malignant tissues is different from expression of all other previously described human B‐cell antigens. In peripheral blood and bone marrow, the antigen appears to be present on all B lymphocytes, with the exception of plasma cells. In tissue, immunohistochemical staining revealed positivity for all known B‐cell compartments; however, pulpa macrophages of the spleen and von Kupffer cells exhibited distinct positivity for CD72 also. Among 83 malignant non‐Hodgkin's lymphomas examined by immunohistochemistry (alkaline phosphatase anti‐alkaline phosphatase technique), all 54 B‐cell lymphomas, including precursor B‐cell lymphomas, Burkitt's lymphomas, germinal center lymphomas, chronic lymphocytic leukemias, and hairy cell leukemias, were CD72 positive, but no T‐cell lymphomas were. Flow cytometry study of more than 80 mainly acute leukemias (52 B‐cell leukemias) showed reactivity with S‐HCL 2 mAb over the full range of B‐cell differentiation. In particular, very early B cells in cytoplasmic Ig (clg)‐negative, CD19‐positive prepre‐B‐cell leukemias and hybrid leukemias (mixed myeloid and B‐cell type) were consistently positive for CD72 on the cell surface. Therefore, CD72 may become an important marker for progenitor B‐cell leukemias.